Noninvasive Urinary Monitoring of Progression in IgA Nephropathy. by Yang, Joshua YC et al.
UCSF
UC San Francisco Previously Published Works
Title
















eScholarship.org Powered by the California Digital Library
University of California
 International Journal of 
Molecular Sciences
Communication
Noninvasive Urinary Monitoring of Progression in
IgA Nephropathy
Joshua Y. C. Yang 1,2 , Reuben D. Sarwal 1, Fernando C. Fervenza 3, Minnie M. Sarwal 1,2,*
and Richard A. Lafayette 4,*
1 Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA
2 KIT Bio, 665 3rd St, Suite 280, San Francisco, CA 94107, USA
3 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA
4 Division of Nephrology and Hypertension, Stanford University, Stanford, CA 94305, USA
* Correspondence: minnie.sarwal@ucsf.edu (M.M.S.); czar@stanford.edu (R.A.L.)
Received: 26 July 2019; Accepted: 7 September 2019; Published: 10 September 2019


Abstract: Standard methods for detecting and monitoring of IgA nephropathy (IgAN) have
conventionally required kidney biopsies or suffer from poor sensitivity and specificity. The Kidney
Injury Test (KIT) Assay of urinary biomarkers has previously been shown to distinguish between
various kidney pathologies, including chronic kidney disease, nephrolithiasis, and transplant rejection.
This validation study uses the KIT Assay to investigate the clinical utility of the non-invasive detection
of IgAN and predicting the progression of renal damage over time. The study design benefits from
longitudinally collected urine samples from an investigator-initiated, multicenter, prospective study,
evaluating the efficacy of corticosteroids versus Rituximab for preventing progressive IgAN. A total
of 131 urine samples were processed for this study; 64 urine samples were collected from 34 IgAN
patients, and urine samples from 64 demographically matched healthy controls were also collected;
multiple urinary biomarkers consisting of cell-free DNA, methylated cell-free DNA, DMAIMO,
MAMIMO, total protein, clusterin, creatinine, and CXCL10 were measured by the microwell-based
KIT Assay. An IgA risk score (KIT-IgA) was significantly higher in IgAN patients as compared to
healthy control (87.76 vs. 14.03, p < 0.0001) and performed better than proteinuria in discriminating
between the two groups. The KIT Assay biomarkers, measured on a spot random urine sample
at study entry could distinguish patients likely to have progressive renal dysfunction a year later.
These data support the pursuit of larger prospective studies to evaluate the predictive performance of
the KIT-IgA score in both screening for non-invasive diagnosis of IgAN, and for predicting risk of
progressive renal disease from IgA and utilizing the KIT score for potentially evaluating the efficacy
of IgAN-targeted therapies.
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1. Introduction
IgA nephropathy (IgAN) remains the most common type of primary chronic glomerulonephritis
worldwide [1]. Its prevalence varies among different groups of people, where IgAN makes up about
20–40% of primary glomerular disease in Asia, and about 15–20% in Northern Europe [2]. The onset of
IgAN may occur at any age, but the condition most frequently develops in patients in their second and
third decades of life [3]. Many patients who present with mild symptoms will not require treatment,
though they will be monitored for disease progression, but up to 40% of patients with IgAN will
eventually develop end-stage renal disease [1]. Trials have established the benefit of agents that
antagonize the renin-angiotensin-aldosterone system (RAAS) in reducing or delaying progression,
but even patients treated with RAAS blockade still face deterioration of their kidney function over
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time [4]. One major issue in the treatment of IgAN is that there are few biomarkers that can predict
progression of disease and monitor the efficacy of treatment [5].
Currently, IgAN is diagnosed by renal biopsy which is often performed to confirm causes of mild
urinary abnormalities, particularly hematuria; however, biopsies are invasive procedures [6] that carry
the risk for complications such as bleeding, and the majority of cases of microscopic hematuria are not
associated with any kidney pathology. Recent advances in the analysis of the urinary proteome suggest
that the excreted polypeptides include disease-specific patterns [7] and as such, much of the current
research has investigated urinary biomarkers of IgA-associated glomerulonephritides. Biomarkers
such as urinary neutrophil gelatinase-associated lipocalin or cystatin C [8] and protein/polypeptide
patterns [9] have been studied in IgAN; however, their discriminative abilities appear modest and many
studies exclude patients undergoing treatment, thus limiting any determination of the monitoring
utility of such biomarkers. As a result, there exists a need for a reliable and non-invasive method to
diagnose and monitor IgAN, especially in the context of treatment.
Recently, the Kidney Injury Test (KIT) Assay was developed by our group as a noninvasive test to
measure kidney injury and function in the context of chronic kidney disease [10], nephrolithiasis [11],
and transplant rejection [12]. The KIT Assay measures a panel of urinary biomarkers in a
microwell-based format that were identified through a combination of proteomics, genomics,
and metabolomics approaches [13–15] to be the most sensitive indicators of various etiologies
of kidney injury and functional changes. In this investigator-initiated, multicenter, prospective
study, we investigated the utility of the KIT Assay, a urine-based, microwell format assay for
the detection of patients with IgAN who were treated with standard of care or with Rituximab.
We additionally investigated the utility of the KIT-IgA score to predict progression of renal functional
decline longitudinally on a subset of these patients who had longitudinally collected samples.
2. Results
2.1. Study Design and Patient Disposition
Sixty-nine spot urine samples were collected from 34 enrolled patients in the IgAN clinical trial
over the study follow-up of 1 year (Figure 1). Patients were randomized at study entry 1:1, to receive
either standard of care (corticosteroids) or Rituximab. Patients had biopsy-confirmed IgAN at study
entry and serial urine samples were collected at study entry, 6 and 12 months. Two or more samples
were available from 25 patients, and a complete set of three time-points were available from 14 patients.
The baseline characteristics and disposition of the 34 patients are listed in Table 1.
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Figure 1. Study design and patient disposition. (Left) In the original trial, 34 patients met inclusion 
criteria and were randomized into Rituximab and standard of care treatment groups. At least one 
urine sample was available from 28 of the 34 patients, with 14 having urine samples at all three 
designated time-points. (Right) Pictorial depiction of patients, treatment, and sample availability. 
Patients were segregated based on treatment, either with standard of care (turquoise) or Rituximab 
(coral), with individual patients as rows. A yellow square indicates a urine sample was available at 
the indicated time-point, while gray indicates that no urine sample was available for analysis due to 
failure to collect or insufficient sample volume. 
Table 1. Baseline characteristics of IgA nephropathy (IgAN) patients. 
Baseline Characteristics IgA Cohort (n = 34) 1 
Age, years 40 (21–63) 
Sex  
• Female 9 
• Male 25 
Race  
• Caucasian 24 
• Asian/Pacific Islander 6 
• Hispanic/Latino 3 
• African American 1 
Weight, kg 89.7 (57–120) 
eGFR, mL/min per 1.73 m2 49 (30–122) 
Treatment  
• Rituximab 17 
• Standard of Care 17 
1 Data are reported as median (range) or count. n indicates the number of patients in the cohort. 
As concluded by the original study, and as shown in Figure 2, there was no statistically 
significant difference between the change in eGFR over the course of the study by treatment with 
Rituximab (coral) over standard of care (teal). However, while some patients maintained or even 
recovered kidney function as seen in an increase in eGFR, some patients had IgAN progression 
with functional decline. This finding motivated us to investigate whether the KIT Assay biomarkers 
could be used to not only detect IgA nephropathy through urine alone, but also predict and 
monitor kidney function changes longitudinally. 
Figure 1. Study design and patient disposition. (Left) In the original trial, 34 patients met inclusion
criteria and were randomized into Rituximab and standard of care treatment groups. At least one urine
sample was available from 28 of the 34 patients, with 14 having urine samples at all three designated
time-points. (Right) Pictorial depiction of patients, treatment, and sample availability. Patients were
segregated based on tre tment, either with standard of care ( urq ois ) or Rituximab (cor l), with
individual p tients as r ws. A yellow squ r indicates a urine sample was available at the indicated
time-point, while gray indicates that no urine sample was available for analysis due to failure to collect
or insufficient sample volume.
Table 1. Baseline characteristics of IgA nephropathy (IgAN) patients.
Baseline Characteristics IgA Cohort (n = 34) 1






• Asian/Pacific Islander 6
• Hispanic/Latino 3
• African American 1
Weight, kg 89.7 (57–120)
eGFR, mL/mi per 1.73 m2 49 (30–122)
Treatment
• Rituximab 17
• Standard of Care 17
1 Data are reported as median (range) or count. n indicates the number of patients in the cohort.
As concluded by the original study, and as shown in Figure 2, there was no statistically significant
difference between the change in eGFR over the course of the study by treatment with Rituximab
(coral) over standard of care (teal). However, while some patients maintained or even recovered
kidney function as seen in an increase in eGFR, some patients had IgAN progression with functional
decline. This finding motivated us to investigate whether the KIT Assay biomarkers could be used to
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Figure 2. Changes in eGFR (by Modification of Diet in Renal Disease (MDRD) [16]) from baseline. 
Data shown here for the change in eGFR values over the time-course of the study for a subset of 14 
patients who had complete urine samples collected at all three study time-points. Each line 
represents an individual patient trajectory. Trajectories in teal represent patients who received 
standard of care while those in salmon represent those who received Rituximab. 
2.2. The KIT Assay Biomarkers Can Discriminate Healthy Controls from Patients with IgA Nephropathy 
Urine samples from 64 healthy control patients were assessed and compared to those collected 
from the IgA nephropathy patients for the KIT biomarkers. A KIT-IgA risk score, ranging from 0 to 
100, was developed on these biomarkers using a Bootstrap Forest ensemble model. The KIT-IgA 
scores for each of the patients in the two groups are depicted in Figure 3A. The KIT-IgA score could 
distinguish between healthy controls (median 14.03, 95% CI 8.94–18.52) and IgA patients (median 
87.76, 95% CI 83.39–90.32) (p < 0.0001). Receiver–operator characteristic curves (Figure 3B) 
comparing the discrimination abilities of the IgA risk score and proteinuria identifies the IgA risk 
score (AUC 0.9935, 95% CI 0.985–1.000) as performing better than proteinuria (AUC 0.9100, 95% CI 
0.855–0.965), suggesting that the KIT-IgA risk score is more sensitive and may detect IgAN earlier 
than proteinuria. For the KIT-IgA risk score, the sensitivity and specificity were 95.5% and 98.4% 
respectively. 
 
Figure 3. The urinary KIT biomarkers could segregate healthy controls from those with IgA 
nephropathy. (A) An IgA risk score ranging from 0 to 100 segregated healthy control patients from 
those with IgA nephropathy. Urine samples were collected from healthy controls (n = 64) who had 
no evidence of kidney disease or injury as assessed by both absence of proteinuria and eGFR greater 
than 120. All urine samples from IgA patients (n = 67) were used, as none of these patients had 
remission of IgA during the treatment duration. (B) Receiver–operator characteristic (ROC) curves 
of the IgA risk score with AUC of 0.994 (p < 0.0001) and proteinuria. For the IgA risk score, the 
sensitivity and specificity were 95.5% and 98.4% respectively. **** p < 0.0001. 
Figure 2. Changes in eGFR (by fi ti n of Diet in Renal Di ase (MDRD [16]) from baseline.
Data shown here for the change i values over the time-course of the study for a subset of
14 patients who had complete urine samples collected at all three study time-points. Each line represents
an individual patient trajectory. Trajectories in teal represent patients who received standard of care
while those in salmon represent those who received Rituximab.
2.2. The KIT Assay Biomarkers Can Discriminate Healthy ontrols from Patients with IgA Nephropathy
Urine samples from 64 healthy control patients were assessed and compared to those collected
from the IgA nephropathy patients for the KIT biomarkers. A KIT-IgA risk score, ranging from 0
to 100, was developed on these biomarkers using a Bootstrap Forest ensemble model. The KIT-IgA
scores for each of the patients in the two groups are depicted in Figure 3A. The KIT-IgA score could
distinguish between healthy controls (median 14.03, 95% CI 8.94–18.52) and IgA patients (median
87.76, 95% CI 83.39–90.32) (p < 0.0001). Receiver–operator characteristic curves (Figure 3B) comparing
the discrimination abilities of the IgA risk score and proteinuria identifies the IgA risk score (AUC
0.9935, 95% CI 0.985–1.000) as performing better than pr teinuria (AUC 0.9100, 95% CI 0.855–0.965),
suggesting that the KIT-IgA risk score is more sen itive and may detect IgAN earlier than proteinuria.
For the KIT-IgA risk score, the sensitivity and specificity were 95.5% and 98.4% respectively.
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Figure 3. The urinary KIT biomarkers could segregate healthy controls from those it I nephropathy.
(A) An IgA risk score ran ing from 0 to 100 segregated healthy control patie ts from those with IgA
nephropathy. Urine samples were collected from healthy controls (n = 64) who had no evidence of
kidney disease or injury as a se sed by both ab nc of pr teinuria and eGFR greater than 120. All urine
samples from IgA patients (n = 67) were used, as none of the p tients had remissio of IgA during
the treatment duration. (B) Receiver–operator characteristic (ROC) curves of the IgA risk score with
AUC of 0.994 (p < 0.0001) and proteinuria. For the IgA risk score, the sensitivity and specificity were
95.5% and 98.4% respectively. **** p < 0.0001.
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2.3. The KIT Assay Biomarkers Can Discriminate Progressors from Non-Progressors and Predict Progression
We further investigated whether the KIT Assay biomarkers and the KIT-IgA score could distinguish
progressors versus non-progressors. Progression was assessed based on a composite clinical evaluation
of changes in proteinuria and eGFR from baseline (>50% increase in proteinuria and/or a 25% reduction
in eGFR) and, as such, was dependent on both urine and serum biomarker values. We first sought to
investigate whether urinary biomarkers alone could be used to classify progressor status. Looking at
the 1-year endpoint biomarkers (Figure 4A), progressor status could be classified using nominal logistic
regression with 100% accuracy based on urinary measurements alone (p = 0.0154). We then investigated
whether midpoint (0.5 year prior to progression determination) and baseline (1 year prior) urinary
biomarkers could predict progression status. We found that the KIT-IgA score could predict progressor
status with 100% accuracy at both time-points (midpoint p = 0.0269, baseline p = 0.0383). For both the
baseline and midpoint predictions, the cfDNA values were the most important predictors, with chi
square likelihood ratios of 25.92 and 141.98, respectively, and with p < 0.0001 for both. However, neither
baseline nor midpoint proteinuria alone could predict progression (Figure 4B). As the progressor
definition was based on a composite of proteinuria and eGFR changes, there was no expectation that
endpoint proteinuria alone could predict progressor status, as reflected in the probabilities. We further
assessed the ability of the baseline urinary biomarkers to predict progression status on the entire set
of patients who had baseline urine samples, regardless of the presence of additional longitudinal
samples. For these 23 urine-patient pairs, the results were similar to the original analysis in that the
KIT biomarkers could segregate progressors from non-progressors with 100% accuracy (p < 0.0001)
(ROC AUC = 1.00).
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receive Rituximab or continue standard care. Baseline Oxford classification score [18] was recorded 
in blinded fashion by an expert renal pathologist. eGFR (by Modification of Diet in Renal Disease 
(MDRD) [16]) or measured creatinine clearance had to be <90 and >30 mL/min per 1.73 m2. To 
establish continued risk, baseline proteinuria needed to be >1000 mg/day while on stable doses of 
Figure 4. KIT Assay biomarker modeling of progression status after one year of treatment. Modeling
was perfor ed on endpoint, midpoint, and baseline biomarker data on either (A) the set of KIT Assay
biomarkers or (B) proteinuria alone. The y-axis shows the probability of progression as determined by
a nominal logistic regression model.
3. Materials and Methods
3.1. Patients and Study Characteristics
Samples were those from a study done in 2017 (NCT00498368) and the study was registered with
clinicaltrials.gov [17]. Patient inclusion and exclusion criteria were as described in the previous study.
Subjects included adults, ages 18–70 years old, with biopsy-proven IgAN within 2 years of enrollment
were included. Patients were excluded if their biopsy showed >50% glomerular sclerosis or interstitial
fibrosis or >10% glomerular crescents. Subjects were then randomly assigned to receive Rituximab or
continue standard care. Baseline Oxford classification score [18] was recorded in blinded fashion by an
expert renal pathologist. eGFR (by Modification of Diet in Renal Disease (MDRD) [16]) or measured
creatinine clearance had to be <90 and >30 mL/min per 1.73 m2. To establish continued risk, baseline
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proteinuria needed to be >1000 mg/day while on stable doses of angiotensin-converting enzyme
inhibitor, angiotensin receptor blocker, or renin inhibitor therapy for at least 2 months. However,
patients who were on dual therapy with agents that inhibit angiotensin II required a lower proteinuria
threshold of >500 mg/day. Baseline BP was controlled to <130/80 mmHg. Patients with secondary
forms of IgAN, such as cirrhosis, were excluded, although subjects with Henoch–Schönlein purpura
nephritis (HSPN) could be included. Patients were excluded if they had previously received Rituximab,
were receiving other immunosuppressive therapy, or had ever received >6 months of prednisone or
other systemic corticosteroid therapy in the past. There was no corticosteroid exposure within 3 months
of study initiation. Randomization was done centrally by a random assignment by prefilled envelopes.
The protocol was approved by the institutional review board of each participating center. The study
was registered with clinicaltrials.gov, protocol NCT00498368. Informed consent was obtained before
all study procedures, and the study adhered to the Declaration of Helsinki.
The primary outcome measures were the change in proteinuria and the change in eGFR from
baseline to 12 months. The secondary outcome was safety related, comparing overall adverse events
and monitoring for potential intervention-specific complications, such as infusion-related reactions,
hypogammaglobulinemia, and infections. Progression was defined as a >50% increase in proteinuria
and/or a 25% reduction in eGFR at the one-year time-point. Results showed that treatment with
Rituximab resulted in statistically insignificant changes in proteinuria or partial remissions that could
not be distinguished from the response to supportive therapy alone.
For the healthy control cohort, urine samples were collected from healthy controls (n = 64) who
had no evidence of kidney disease or injury as assessed by both absence of proteinuria and eGFR
greater than 120. Demographics of this cohort include a median age of 24 (range 2 to 64), median
weight of 57.5 kg (range 13.7 to 120.2), 53.1% female, 9.4% African American, and median eGFR of 132
(range 120 to 213).
3.2. Urine Sample Processing
Voided urine samples were collected in sterile containers. Urine samples were centrifuged at
2000× g for 30 min at 4 ◦C. The supernatant was separated from the urine pellet containing cells and
cell debris. The pH of the supernatant was adjusted to 7.0 using Tris-HCl and stored at −80 ◦C in the
UCSF Biorepository until further analysis.
3.3. KIT Assay Biomarkers
Measurement of the KIT Assay biomarkers was performed as previously described [10].
Total protein was measured using the PierceTM Coomassie Plus Assay Kit (Thermo Fisher
Scientific, Waltham, MA, USA). Urinary creatinine was measured using the Creatinine
Assay Kit (BioAssay Systems, Hayward, CA, USA) as a method for urinary concentration
and hydration status normalization. Briefly, cell-free DNA (cfDNA), methylated cell-free
DNA (m-cfDNA), CXCL10, Clusterin, (Dimethylamino)iminomethyl-ornithine (DMAIMO), and
(Methylamino)(methylimino)methyl-ornithine (MAMIMO), were measured using the KIT Assay (KIT
Bio, San Francisco, CA, USA), a set of in-house developed ELISA assays. Microwell plate readings
were measured using a SpectraMax iD3 Multi-Mode Microplate Reader (Molecular Devices, San Jose,
CA, USA). All assays were run in duplicates.
3.4. Statistical Analysis
Comparisons involving two groups were performed using the nonparametric Mann–Whitney U
test. Comparisons involving three groups were performed using the nonparametric Kruskal–Wallis
test with Dunn’s post-hoc multiple comparisons correction. The IgA risk score was determined using a
Bootstrap Forest ensemble model by averaging numerous decision trees each fit to a bootstrap sample
of the training data. The final prediction is the average of the predicted values over all the decision trees.
Specifically, six trees were used in the forest, with a minimum of ten splits per tree and a minimum
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size split of five. The number of splits for trees 1–6 were 9, 17, 15, 7, 13, and 11 respectively. The top
contributing biomarkers as based on G2 were total protein, MAMIMO, creatinine, and DMAIMO,
with G2 values of 36.02, 21.12, 9.72, and 6.74 respectively. The overall statistics for the Entropy R2 was
0.7422, Generalized R2 was 0.8568, and Root Mean Square Error (RMSE) was 0.1996.
Modeling of progressor status was done using nominal logistic regression. All analyses were
performed using either GraphPad Prism 8.0.2 (GraphPad Software, Carlsbad, CA, USA) or JMP 14.3
(SAS Institute, Cary, NC, USA).
4. Discussion
In this study, we used urine samples from IgA nephropathy (IgAN) patients to evaluate the
predictive capacity of the KIT Assay biomarkers to discriminate IgAN from healthy controls as well
as predict progression of renal functional decline. Our results show that these urinary biomarkers
could distinguish between healthy control patients and those with IgAN better than urinary protein
alone. Furthermore, the biomarkers could predict progressor status up to one year in advance of status
determination while urinary protein could not.
Such findings are important because IgAN is the most prevalent chronic glomerular disease
worldwide [19], with diagnosis historically requiring kidney biopsy. While recent studies have identified
serum and urinary biomarkers that can diagnose IgAN with high accuracy [7,8,20], the clinical utility
of individual biomarkers is limited by the high overlap between the healthy and diseased ranges of
these biomarkers in an individual and temporal manner. Such biomarkers, while indicative of IgAN,
have shown less utility in predicting progression of disease. While some studies have suggested the
use of GC–MS and similar technologies to identify a panel of biomarkers, these proteomic studies are
not easily transferrable to the clinical setting. Identifying biomarkers that not only can identify IgAN
but can also predict progression is important for the future development and evaluation of therapies
that seek to treat and prevent functional decline in IgAN.
The multi-hit hypothesis for the pathogenesis of IgA nephropathy is the leading theory behind the
mechanism of progression [20]. In this hypothesis, deposition of IgA1-containing circulating immune
complexes in the glomeruli induce renal injury by subsequent induction of local cytokine, growth factor,
and complement system production and activation [21–24]. While currently approved therapies for
IgAN are largely non-IgAN specific and consist of supportive therapy with corticosteroids and blood
pressure control [25], future directed therapies targeting the specific “hits” in IgAN will address these
acute causes of glomerular injury. Monitoring the efficacy of such therapies will require biomarkers
that not only reflect kidney function, but also convey the acute status of kidney injury and resolution
of that injury.
We had previously validated the utility of the biomarkers comprising the KIT Assay in chronic
kidney disease [10], chronic lung transplant rejection [26,27], nephrolithiasis [11], and kidney transplant
rejection [12,28], suggesting its utility across a range of diseases and chronicity states. The KIT Assay
biomarkers are measured in a microwell format, contributing to their ease of use and deployment.
Additionally, urine is a completely noninvasive biofluid that is available in virtually unlimited quantities,
enabling a frequency of monitoring that can be adjusted to the functional status of the patient. Due to
the acute and chronic injury mechanism present in IgAN [29], we investigated whether the KIT Assay
biomarkers could also be applied to detection of IgAN as well as prediction of progression status.
We have discussed the rationale of the KIT Assay biomarkers previously [10], with selection of
these biomarkers due to the various temporal and regional differences in levels as dependent upon
renal injury and function. While proteinuria has been shown to be a predictor of outcome in IgAN [30]
and is a commonly used endpoint, proteinuria did not perform as well as the composite IgA risk score
in discriminating patients with IgAN from healthy controls, likely because many patients with IgAN
present with low levels of proteinuria despite disease progression [31]. That the KIT-IgA risk score
could identify IgAN more accurately is likely due to the composite integration of functional, injury,
and renal-specific markers that may reflect IgAN across a spectrum of disease states.
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Further, proteinuria alone was not a significant predictor for progression at one-year of treatment
duration measured at either the baseline or midpoint time-points. It is notable that the cfDNA values at
baseline and midpoint were the strongest predictors of progression at the one-year timepoint. Urinary
cfDNA has been previously reported to be a sensitive indicator of kidney injury and reflects ongoing
damage to the kidney prior to functional changes or decline [15,32,33]. This finding is in concordance
with these reports, suggesting that while progression may be defined by functional measures such
as eGFR and proteinuria, the underlying cause of such progression may be acute injury such as that
measured by cfDNA burden. As such, measurement of cfDNA, as done in the KIT Assay, may be
beneficial for measuring the efficacy of treatment in IgAN.
In summary, our data indicate that the non-invasive KIT Assay panel of urinary biomarkers can
distinguish between healthy controls and patients with IgAN. Furthermore, this panel could monitor
progression of disease and changes in kidney function. We believe that the KIT-IgA score would
have great utility in (1) screening for IgAN in patients with hematuria, as a replacement for biopsy as
done in many Asian countries; (2) diagnosis; (3) monitoring efficacy of treatment; and (4) predicting
progression and monitoring disease activity. While our sample size is limited by the small size of the
parent study, these results add to a growing body of evidence of the generalizability and utility of
the KIT Assay biomarkers in renal disease and beyond. Additionally, while all comparisons in this
study were between healthy control and IgAN patients, we have planned additional studies where
we will include samples from patients with other types of renal diseases so that we can assess the
performance of these and other biomarkers in discriminating IgAN from other nephropathies. Future
studies using additional kidney disease cohorts will clarify whether there is a specific pattern among
these biomarkers to discriminate one disease from another. Future multi-center, prospective studies
are planned to further build on the clinical utility of these observations to assess serial performance of
the KIT assay in IgAN patients as a non-invasive tool to monitor disease progression and evaluate the
efficacy of new reno-protective therapies for IgA disease.
Author Contributions: M.M.S. and R.A.L. designed the study and experiments; J.Y.C.Y. and R.D.S. carried out
experiments; J.Y.C.Y., M.M.S., and R.A.L. analyzed the data; J.Y.C.Y. made the figures; J.Y.C.Y., R.D.S., F.C.F.,
M.M.S., and R.A.L. drafted and revised the paper; all authors revised the manuscript critically for important
intellectual content and approved the final version of the manuscript. R.A.L. had full access to all the data in the
study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Funding: This research and the APC was funded by Genentech, grant number 249 (ML 01579), via an Investigator
initiated study award to Minnie Sarwal linked to the parent IgA clinical IST trial. This research was funded by the
Sarwal Laboratory of the University of California, San Francisco (UCSF), via startup funding.
Acknowledgments: We are grateful for the help from physicians, clinical coordinators, research personnel,
patients, and patient families.
Conflicts of Interest: The samples from the patient cohort in this study came from an investigator-initiated study
sponsored by Genentech/Roche, Inc. and the Fulk Family Foundation. The sponsors had no role in study design,
protocol development, data analysis, or preparation of the manuscript. M.M.S. and J.Y.C.Y. are founders of KIT
Bio, Inc. (San Francisco, CA), now operating under NephroSant, IP for which is exclusively owned by the Regents,
University of California San Francisco and licensed to KIT Bio. R.L. is a scientific advisor of KIT Bio. All other
authors declare no conflict of interest.
Abbreviations
AUC area-under-curve
BMI body mass index
cfDNA cell-free deoxyribonucleic acid
DMAIMO (dimethylamino)iminomethyl-ornithine
eGFR estimated glomerular filtration rate
GC–MS gas chromatography–mass spectrometry
HSPN Henoch–Schönlein purpura nephritis
IgAN immunoglobulin alpha nephropathy
KIT Kidney Injury Test
Int. J. Mol. Sci. 2019, 20, 4463 9 of 10
m-cfDNA methylated cfDNA
MAMIMO (methylamino)(methylimino)methyl-ornithine




1. Wyatt, R.J.; Julian, B.A. IgA Nephropathy. N. Engl. J. Med. 2013, 368, 2402–2414. [CrossRef]
2. D’Amico, G. Clinical features and natural history in adults with IgA nephropathy. Am. J. Kidney Dis. 1988,
12, 353–357. [CrossRef]
3. Yap, H.K.; Quek, C.M.; Shen, Q.; Joshi, V.; Chia, K.S. Role of urinary screening programmes in children in the
prevention of chronic kidney disease. Ann. Acad. Med. Singap. 2005, 34, 3–7. [PubMed]
4. Boyd, J.K.; Cheung, C.K.; Molyneux, K.; Feehally, J.; Barratt, J. An update on the pathogenesis and treatment
of IgA nephropathy. Kidney Int. 2012, 81, 833–843. [CrossRef] [PubMed]
5. Maixnerova, D.; Reily, C.; Bian, Q.; Neprasova, M.; Novak, J.; Tesar, V. Markers for the progression of IgA
nephropathy. J. Nephrol. 2016, 29, 535–541. [CrossRef]
6. Donadio, J.V.; Joseph, P. Grande IgA Nephropathy. N. Engl. J. Med. 2002, 347, 738–748. [CrossRef] [PubMed]
7. Julian, B.A.; Wittke, S.; Haubitz, M.; Zürbig, P.; Schiffer, E.; McGuire, B.M.; Wyatt, R.J.; Novak, J. Urinary
biomarkers of IgA nephropathy and other IgA-associated renal diseases. World J. Urol. 2007, 25, 467–476.
[CrossRef] [PubMed]
8. Ding, H.; He, Y.; Li, K.; Yang, J.; Li, X.; Lu, R.; Gao, W. Urinary neutrophil gelatinase-associated lipocalin
(NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin. Immunol. 2007,
123, 227–234. [CrossRef] [PubMed]
9. Haubitz, M.; Wittke, S.; Weissinger, E.M.; Walden, M.; Rupprecht, H.D.; Floege, J.; Haller, H.; Mischak, H.
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005, 67,
2313–2320. [CrossRef]
10. Watson, D.; Yang, J.Y.C.; Sarwal, R.D.; Sigdel, T.K.; Liberto, J.M.; Damm, I.; Louie, V.; Sigdel, S.; Livingstone, D.;
Soh, K.; et al. A Novel Multi-Biomarker Assay for Non-Invasive Detection and Quantitative Monitoring of
Kidney Injury. J. Clin. Med. 2019, 8, 499. [CrossRef]
11. Yang, J.Y.C.; Sarwal, R.D.; Ky, K.; Dong, V.; Stoller, M.; Watson, D.; Sarwal, M.M.; Chi, T. Non-Radiologic
Assessment of Kidney Stones by KIT, a Spot Urine Assay. Br. J. of Urol. Int. 2019. under review.
12. Yang, J.Y.C.; Sarwal, R.D.; Sigdel, T.K.; Sarwal, M.M. Predicting Transplant Rejection by a Composite Urinary
Injury Score. Am. J. Transpl. 2019, 17, 519.
13. Sigdel, T.K.; Gao, Y.; He, J.; Wang, A.; Nicora, C.D.; Fillmore, T.L.; Shi, T.; Webb-Robertson, B.-J.; Smith, R.D.;
Qian, W.-J.; et al. Mining the human urine proteome for monitoring renal transplant injury. Kidney Int. 2016,
89, 1244–1252. [CrossRef] [PubMed]
14. Yang, J.Y.C.; Sigdel, T.K.; Sarwal, M.M. Self-antigens and rejection: A proteomic analysis. Curr. Opin. Organ
Transpl. 2016, 21, 362–367. [CrossRef] [PubMed]
15. Yang, J.Y.C.; Sarwal, M.M. Transplant genetics and genomics. Nat. Rev. Genet. 2017, 18, 309–326. [CrossRef]
[PubMed]
16. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A more accurate method to estimate
glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal
Disease Study Group. Ann. Intern. Med. 1999, 130, 461–470. [CrossRef]
17. Lafayette, R.A.; Canetta, P.A.; Rovin, B.H.; Appel, G.B.; Novak, J.; Nath, K.A.; Sethi, S.; Tumlin, J.A.; Mehta, K.;
Hogan, M.; et al. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and
Renal Dysfunction. J. Am. Soc. Nephrol. 2017, 28, 1306–1313. [CrossRef]
18. Cattran, D.C.; Coppo, R.; Cook, H.T.; Feehally, J.; Roberts, I.S.D.; Troyanov, S.; Alpers, C.E.; Amore, A.;
Barratt, J.; Berthoux, F.; et al. The Oxford classification of IgA nephropathy: Rationale, clinicopathological
correlations, and classification. Kidney Int. 2009, 76, 534–545. [CrossRef]
19. Schena, F.P.; Nistor, I. Epidemiology of IgA Nephropathy: A Global Perspective. Semin. Nephrol. 2018, 38,
435–442. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 4463 10 of 10
20. Suzuki, H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin. Exp. Nephrol. 2019,
23, 26–31. [CrossRef]
21. Lai, K.N. Pathogenesis of IgA nephropathy. Nat. Rev. Nephrol. 2012, 8, 275–283. [CrossRef] [PubMed]
22. Sigdel, T.K.; Woo, S.H.; Dai, H.; Khatri, P.; Li, L.; Myers, B.; Sarwal, M.M.; Lafayette, R.A. Profiling of
Autoantibodies in IgA Nephropathy, an Integrative Antibiomics Approach. J. Am Soc. Nephrol. 2011, 6,
2775–2784. [CrossRef] [PubMed]
23. Woo, S.H.; Sigdel, T.K.; Dinh, V.T.; Vu, M.T.; Sarwal, M.M.; Lafayette, R.A. Mapping novel immunogenic
epitopes in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 2015, 10, 372–381. [CrossRef] [PubMed]
24. Rizk, D.V.; Saha, M.K.; Hall, S.; Novak, L.; Brown, R.; Huang, Z.-Q.; Fatima, H.; Julian, B.A.; Novak, J.
Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies
Specific for Galactose-Deficient IgA1. J. Am. Soc. Nephrol. 2019, 30, 9. [CrossRef] [PubMed]
25. Floege, J.; Eitner, F. Current Therapy for IgA Nephropathy. J. Am. Soc. Nephrol. 2011, 22, 1785–1794.
[CrossRef] [PubMed]
26. Yang, J.Y.C.; Verleden, S.E.; Zarinsefat, A.; Vanaudenaerde, B.M.; Vos, R.; Verleden, G.M.; Sarwal, R.D.;
Sigdel, T.K.; Liberto, J.M.; Damm, I.; et al. Cell-Free DNA and CXCL10 Derived from Bronchoalveolar Lavage
Predict Lung Transplant Survival. J. Clin. Med. 2019, 8, 9. [CrossRef] [PubMed]
27. Sacreas, A.; Yang, J.Y.C.; Vanaudenaerde, B.M.; Sigdel, T.K.; Liberto, J.M.; Damm, I.; Verleden, G.M.; Vos, R.;
Verleden, E.; Sarwal, M.M. The common rejection module in chronic rejection post lung transplantation.
PLoS ONE 2018, 13, 1–16. [CrossRef]
28. Sigdel, T.K.; Yang, J.Y.C.; Bestard, O.; Schroeder, A.; Hsieh, S.-C.; Liberto, J.M.; Damm, I.; Geraedts, A.C.M.;
Sarwal, M.M. A urinary Common Rejection Module (uCRM) score for non-invasive kidney transplant
monitoring. PLoS ONE 2019, 7, 1–15. [CrossRef] [PubMed]
29. Kusano, T.; Takano, H.; Kang, D.; Nagahama, K.; Aoki, M.; Morita, M.; Kaneko, T.; Tsuruoka, S.; Shimizu, A.
Endothelial cell injury in acute and chronic glomerular lesions in patients with IgA nephropathy. Hum. Pathol.
2016, 49, 135–144. [CrossRef]
30. Reich, H.N.; Troyanov, S.; Scholey, J.W.; Cattran, D.C. Remission of Proteinuria Improves Prognosis in IgA
Nephropathy. J. Am. Soc. Nephrol. 2007, 18, 3177–3183. [CrossRef]
31. Gutiérrez, E. IgA nephropathy: Is a new approach beyond proteinuria necessary? Pediatr. Nephrol. 2019,
921–924. [CrossRef] [PubMed]
32. Burnham, P.; Dadhania, D.; Heyang, M.; Chen, F.; Westblade, L.F.; Suthanthiran, M.; Lee, J.R.; De Vlaminck, I.
Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. Nat. Commun.
2018, 9, 1–10. [CrossRef] [PubMed]
33. Celec, P.; Vlková, B.; Lauková, L.; Bábícˇková, J.; Boor, P. Cell-free DNA: The role in pathophysiology and as a
biomarker in kidney diseases. Expert Rev. Mol. Med. 2018, 20, 1–14. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
